These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases. Peker A; Çiçek O; Soydal Ç; Küçük NÖ; Bilgiç S Diagn Interv Radiol; 2015; 21(1):54-9. PubMed ID: 25430526 [TBL] [Abstract][Full Text] [Related]
4. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres. Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356 [TBL] [Abstract][Full Text] [Related]
5. Determination of Tumor Dose Response Thresholds in Patients with Chemorefractory Intrahepatic Cholangiocarcinoma Treated with Resin and Glass-based Y90 Radioembolization. Cheng B; Villalobos A; Sethi I; Wagstaff W; Galt J; Brandon D; Schuster DM; Bercu Z; Majdalany B; Kokabi N Cardiovasc Intervent Radiol; 2021 Aug; 44(8):1194-1203. PubMed ID: 33890170 [TBL] [Abstract][Full Text] [Related]
6. Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors. Jia Z; Paz-Fumagalli R; Frey G; Sella DM; McKinney JM; Wang W J Gastroenterol Hepatol; 2017 Sep; 32(9):1617-1623. PubMed ID: 28132407 [TBL] [Abstract][Full Text] [Related]
7. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study. Gangi A; Shah J; Hatfield N; Smith J; Sweeney J; Choi J; El-Haddad G; Biebel B; Parikh N; Arslan B; Hoffe SE; Frakes JM; Springett GM; Anaya DA; Malafa M; Chen DT; Chen Y; Kim RD; Shridhar R; Kis B J Vasc Interv Radiol; 2018 Aug; 29(8):1101-1108. PubMed ID: 30042074 [TBL] [Abstract][Full Text] [Related]
8. Resin Versus Glass Microspheres for Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436 [TBL] [Abstract][Full Text] [Related]
9. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma. Allimant C; Kafrouni M; Delicque J; Ilonca D; Cassinotto C; Assenat E; Ursic-Bedoya J; Pageaux GP; Mariano-Goulart D; Aho S; Guiu B J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745 [TBL] [Abstract][Full Text] [Related]
10. Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis. Buettner S; Braat AJAT; Margonis GA; Brown DB; Taylor KB; Borgmann AJ; Kappadath SC; Mahvash A; IJzermans JNM; Weiss MJ; Lamarca A; Bell JK; Valle JW; Hagendoorn J; Koerkamp BG; Sze DY; Lam MGEH J Vasc Interv Radiol; 2020 Jul; 31(7):1035-1043.e2. PubMed ID: 32473757 [TBL] [Abstract][Full Text] [Related]
11. Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis. Frilling A; Clift AK; Braat AJAT; Alsafi A; Wasan HS; Al-Nahhas A; Thomas R; Drymousis P; Habib N; Tait PN HPB (Oxford); 2019 Jul; 21(7):773-783. PubMed ID: 30733049 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres. Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137 [TBL] [Abstract][Full Text] [Related]
13. Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases. Tomozawa Y; Jahangiri Y; Pathak P; Kolbeck KJ; Schenning RC; Kaufman JA; Farsad K J Vasc Interv Radiol; 2018 Jun; 29(6):858-865. PubMed ID: 29724520 [TBL] [Abstract][Full Text] [Related]
14. Nezami N; Kokabi N; Camacho JC; Schuster DM; Xing M; Kim HS Nucl Med Biol; 2018 Apr; 59():22-28. PubMed ID: 29448165 [TBL] [Abstract][Full Text] [Related]
15. Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver. Kennedy A; Coldwell D; Sangro B; Wasan H; Salem R Am J Clin Oncol; 2012 Aug; 35(4):393-8. PubMed ID: 21278561 [TBL] [Abstract][Full Text] [Related]
16. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Rhee TK; Lewandowski RJ; Liu DM; Mulcahy MF; Takahashi G; Hansen PD; Benson AB; Kennedy AS; Omary RA; Salem R Ann Surg; 2008 Jun; 247(6):1029-35. PubMed ID: 18520231 [TBL] [Abstract][Full Text] [Related]
17. Outcomes of Radioembolization in Patients with Chemorefractory Colorectal Cancer Liver Metastasis: a Single-Center Experience. Türk G; Eldem G; Kılıçkap S; Bozkurt FM; Salancı BV; Çil BE; Peynircioğlu B; Yalçın Ş; Balkancı F J Gastrointest Cancer; 2019 Jun; 50(2):236-243. PubMed ID: 29354877 [TBL] [Abstract][Full Text] [Related]
18. Can C-arm cone-beam CT detect a micro-embolic effect after TheraSphere radioembolization of neuroendocrine and carcinoid liver metastasis? Pellerin O; Lin M; Bhagat N; Shao W; Geschwind JF Cancer Biother Radiopharm; 2013; 28(6):459-65. PubMed ID: 23484809 [TBL] [Abstract][Full Text] [Related]